Pathogen reduction made simple

Safeguarding the blood supply is critical. Pathogen reduction provides you that
added measure of security against disease-causing agents, including viruses,
parasites, bacteria and white blood cells.
Naturally, you want a partner you can trust.
The Mirasol Pathogen Reduction Technology (PRT) system uniquely uses the
properties of ribofavin (vitamin B2) and ultraviolet light to reduce the infectious
pathogen load and inactivate residual white blood cells in blood products*.
The Mirasol system renders pathogens harmless by using a non-mutagenic,
non-toxic method, eliminating the need to remove photochemical agents prior
to transfusion making your treated blood products immediately available
to treat patients.
Using a single, integrated system for platelets and plasma, CaridianBCTs
proprietary process delivers:
Safety | Effcacy | Simplicity
*The Mirasol system has received the CE mark for platelets and plasma and is under development for the treatment of whole blood
Helping you keep the blood supply
safe is our highest priority.
The Mirasol

system shines new

light on pathogen reduction.
L e a r n m o r e
T h e M i r a s o l P R T s y s t e m c a n h e l p y o u p r o v i d e s a f e r b l o o d p r o d u c t s t o d a y .
C o n t a c t y o u r C a r i d i a n B C T s a l e s r e p r e s e n t a t i v e o r v i s i t w w w . c a r i d i a n b c t . c o m
f o r a d d i t i o n a l i n f o r m a t i o n .
2010 CaridianBCT, Inc. PN 306690-232
CaridianBCT, Inc.
10811 W. Collins Avenue
Lakewood, Colorado 80215-4440
USA
USA Phone: 1.877.339.4228
Phone: +1.303.231.4357
Fax: +1.303.542.5215
CaridianBCT Europe N.V.
Europe, Middle East and Africa
Ikaroslaan 41
1930 Zaventem
Belgium
Phone: +32.2.715.05.90
Fax: +32.2.721.07.70
CaridianBCT (Asia Pacifc) Ltd.
Room 3903-3903A, 39/F
New York Life Tower, Windsor House
311 Gloucester Road
Causeway Bay, Hong Kong
Phone: +852.2283.0700
Fax: +852.2576.1311
CaridianBCT Latin America
Juncal 1311 4th Floor
C1062ABO
Buenos Aires
Argentina
Phone: +54.11.5530.5200
Fax: +54.11.5530.5201
www.caridianbct.com
The Mirasol system is designed to be effective against a broad range of
pathogens while still maintaining the quality of apheresis and whole
blood-derived blood products. Performance demonstrated against:
a Viruses: Enveloped and non-enveloped
1-3
a Bacteria: Gram negative and gram positive
4
a Parasites
5-9
Safety established
Mirasol-treated components have been shown to be safe for transfusion recipients as well as for those
who handle blood products.
Ribofavin is non-toxic and non-mutagenic; no additional precautionary measures necessary for staff
Ribofavin and its photoproducts are already present in human blood and do not need to be removed
from blood products prior to transfusion
13
The safety of the Mirasol process has been demonstrated through extensive toxicology testing
14
No adverse events were attributed to the use of Mirasol-treated platelet products or to the use of the
Mirasol PRT system in a well-controlled patient trial
15
Effcacy maintained
Reduce pathogen load while providing quality platelets and fresh frozen plasma (FFP).
The MIRACLE clinical trial confrmed no increased need for platelet or red blood cell transfusions
in patients receiving Mirasol-treated platelets
15
This trial also showed Corrected Count Increments (CCI) remained stable throughout multiple
transfusions of Mirasol-treated platelets
15

Mirasol-treated FFP preserves levels of coagulants and anticoagulants that meet the
Council of Europe guidelines for untreated FFP
16-18

Simplicity by design
Easy to learn. Easy to operate. Flexible. Limited handling and minimal product loss with the Mirasol
process help keep your operations effcient. In addition, our fully integrated data capture and storage
software system, the Mirasol Manager, ensures accurate reporting and simplifed data management.
Platelets are ready to
store* or transfuse
Plasma is ready to store
after transfer to fnal
freezing/storage bag
Transfer product to
illumination bag
Add
ribofavin
Illuminate for
4 to 10 minutes 1 2 3
References
1. Ruane PH, et al., Photochemical Inactivation of Selected Viruses and Bacteria in
Platelet Concentrates Using Ribofavin and Light. Transfusion 2004; 44: 877-885.
2. Goodrich RP, et al., The Mirasol PRT System for Pathogen Reduction of Platelets
and Plasma: An Overview of Current Status and Future Trends. Transfusion and
Apheresis Science 2006; 35 (1): 5-17.
3. Goodrich RP, et al., Chapter 5: The Antiviral and Antibacterial Properties of
Ribofavin and Light: Applications to Blood Safety and Transfusion Medicine.
Flavins: Photochemistry and Photobiology, Vol. 6, 2006, Royal Society of
Chemistry; Cambridge, United Kingdom. E Silva and AM Edwards, editors.
4. Goodrich RP, et al., A Laboratory Comparison of Pathogen Reduction
Technology Treatment and Culture of Platelet Products for Addressing Bacterial
Contamination Concerns. Transfusion 2009; 49: 1205-1216.
5. Cardo LJ, et al., Pathogen Inactivation of Leishmania Donovani Infantum in
Plasma and Platelet Concentrates Using Ribofavin and Ultraviolet Light.
Vox Sanguinis 2006; 90: 85-91.
6. Sullivan J, et al., Pathogen Inactivation of Plasmodium Falciparum in Plasma
and Platelet Concentrates With Ribofavin and UV Light. Vox Sanguinis 2008;
95 (Suppl. 1): 278-279.
7. Cardo LJ, et al., Pathogen Inactivation of Trypanosoma Cruzi in Plasma and
Platelet Concentrates Using Ribofavin and Ultraviolet Light. Transfusion and
Apheresis Science 2007; 37 (2): 131-137.
8. Tonnetti L, et al., Evaluation of the Mirasol Platelet Reduction Technology System
Against Babesia Microti in Apheresis Platelets and Plasma. Transfusion 2010,
in press.
9. Rentas F, et al., Inactivation of Orientia Tsutsugamushi in Red Blood Cells,
Plasma, and Platelets With Ribofavin and Light, as Demonstrated in an Animal
Model. Transfusion 2007; 47: 240-247.
10. Fast LD, et al., Functional Inactivation of White Blood Cells by Mirasol
Treatment. Transfusion 2006; 46: 642-648.
11. Fast LD, et al., Mirasol PRT Treatment of Donor White Blood Cells Prevents
the Development of Xenogeneic Graft-Versus-Host Disease in Rag
2-/-c-/-
Double
Knockout Mice. Transfusion 2006; 46: 1553-1560.
12. Asano H, et al., Treatment With Ribofavin and Ultraviolet Light Prevents
Alloimmunization to Platelet Transfusions and Cardiac Transplants.
Transplantation 2007; 84 (9): 1174-1182.
13. Hardwick CC, et al., Separation, Identifcation and Quantifcation of Ribofavin
and Its Photoproducts in Blood Products Using High-Performance Liquid
Chromotography With Fluorescence Detection: A Method to Support Pathogen
Reduction Technology. Photochemistry and Photobiology 2004; 80 (3): 609-615.
14. Reddy HL, et al., Toxicity Testing of a Novel Ribofavin-Based Technology for
Pathogen Reduction and White Blood Cell Inactivation. Transfusion Medicine
Reviews 2008; 22 (2): 133-153.
15. The Mirasol Clinical Evaluation Study Group, A Randomized Controlled Clinical
Trial Evaluating the Performance and Safety of Platelets Treated With Mirasol
Pathogen Reduction Technology. Transfusion 2010, in press.
16. Smith J and G Rock, Protein Quality in Mirasol Pathogen Reduction Technology-
Treated, Apheresis-Derived Fresh-Frozen Plasma. Transfusion 2010; 50: 926-931.
17. Hornsey VS, et al., Pathogen Reduction of Fresh Plasma Using Ribofavin and
Ultraviolet Light: Effects on Plasma Coagulation Proteins. Transfusion 2009 49:
2167-2172.
18. Larrea L, et al., The Infuence of Ribofavin Photochemistry on Plasma
Coagulation Factors. Transfusion and Apheresis Science 2009; 41: 199-204.
* Platelet additive solution (PAS) may need to be added after illumination to platelet concentrates with reduced plasma content to ensure adequate storage
conditions for up to 5 days
a White blood cells (WBCs): Inactivation
of WBCs in donated blood products may
reduce immunological complications of
transfusion
10-12
YOUR SYSTEM FOR
PLATELETS AND PLASMA
Mirasol PRT is the obvious choice
for pathogen reduction
Pathogen reduction made simple
Safeguarding the blood supply is critical. Pathogen reduction provides you that
added measure of security against disease-causing agents, including viruses,
parasites, bacteria and white blood cells.
Naturally, you want a partner you can trust.
The Mirasol Pathogen Reduction Technology (PRT) system uniquely uses the
properties of ribofavin (vitamin B2) and ultraviolet light to reduce the infectious
pathogen load and inactivate residual white blood cells in blood products*.
The Mirasol system renders pathogens harmless by using a non-mutagenic,
non-toxic method, eliminating the need to remove photochemical agents prior
to transfusion making your treated blood products immediately available
to treat patients.
Using a single, integrated system for platelets and plasma, CaridianBCTs
proprietary process delivers:
Safety | Effcacy | Simplicity
*The Mirasol system has received the CE mark for platelets and plasma and is under development for the treatment of whole blood
Helping you keep the blood supply
safe is our highest priority.
The Mirasol

system shines new

light on pathogen reduction.
L e a r n m o r e
T h e M i r a s o l P R T s y s t e m c a n h e l p y o u p r o v i d e s a f e r b l o o d p r o d u c t s t o d a y .
C o n t a c t y o u r C a r i d i a n B C T s a l e s r e p r e s e n t a t i v e o r v i s i t w w w . c a r i d i a n b c t . c o m
f o r a d d i t i o n a l i n f o r m a t i o n .
2010 CaridianBCT, Inc. PN 306690-232
CaridianBCT, Inc.
10811 W. Collins Avenue
Lakewood, Colorado 80215-4440
USA
USA Phone: 1.877.339.4228
Phone: +1.303.231.4357
Fax: +1.303.542.5215
CaridianBCT Europe N.V.
Europe, Middle East and Africa
Ikaroslaan 41
1930 Zaventem
Belgium
Phone: +32.2.715.05.90
Fax: +32.2.721.07.70
CaridianBCT (Asia Pacifc) Ltd.
Room 3903-3903A, 39/F
New York Life Tower, Windsor House
311 Gloucester Road
Causeway Bay, Hong Kong
Phone: +852.2283.0700
Fax: +852.2576.1311
CaridianBCT Latin America
Juncal 1311 4th Floor
C1062ABO
Buenos Aires
Argentina
Phone: +54.11.5530.5200
Fax: +54.11.5530.5201
www.caridianbct.com
The Mirasol system is designed to be effective against a broad range of
pathogens while still maintaining the quality of apheresis and whole
blood-derived blood products. Performance demonstrated against:
a Viruses: Enveloped and non-enveloped
1-3
a Bacteria: Gram negative and gram positive
4
a Parasites
5-9
Safety established
Mirasol-treated components have been shown to be safe for transfusion recipients as well as for those
who handle blood products.
Ribofavin is non-toxic and non-mutagenic; no additional precautionary measures necessary for staff
Ribofavin and its photoproducts are already present in human blood and do not need to be removed
from blood products prior to transfusion
13
The safety of the Mirasol process has been demonstrated through extensive toxicology testing
14
No adverse events were attributed to the use of Mirasol-treated platelet products or to the use of the
Mirasol PRT system in a well-controlled patient trial
15
Effcacy maintained
Reduce pathogen load while providing quality platelets and fresh frozen plasma (FFP).
The MIRACLE clinical trial confrmed no increased need for platelet or red blood cell transfusions
in patients receiving Mirasol-treated platelets
15
This trial also showed Corrected Count Increments (CCI) remained stable throughout multiple
transfusions of Mirasol-treated platelets
15

Mirasol-treated FFP preserves levels of coagulants and anticoagulants that meet the
Council of Europe guidelines for untreated FFP
16-18

Simplicity by design
Easy to learn. Easy to operate. Flexible. Limited handling and minimal product loss with the Mirasol
process help keep your operations effcient. In addition, our fully integrated data capture and storage
software system, the Mirasol Manager, ensures accurate reporting and simplifed data management.
Platelets are ready to
store* or transfuse
Plasma is ready to store
after transfer to fnal
freezing/storage bag
Transfer product to
illumination bag
Add
ribofavin
Illuminate for
4 to 10 minutes 1 2 3
References
1. Ruane PH, et al., Photochemical Inactivation of Selected Viruses and Bacteria in
Platelet Concentrates Using Ribofavin and Light. Transfusion 2004; 44: 877-885.
2. Goodrich RP, et al., The Mirasol PRT System for Pathogen Reduction of Platelets
and Plasma: An Overview of Current Status and Future Trends. Transfusion and
Apheresis Science 2006; 35 (1): 5-17.
3. Goodrich RP, et al., Chapter 5: The Antiviral and Antibacterial Properties of
Ribofavin and Light: Applications to Blood Safety and Transfusion Medicine.
Flavins: Photochemistry and Photobiology, Vol. 6, 2006, Royal Society of
Chemistry; Cambridge, United Kingdom. E Silva and AM Edwards, editors.
4. Goodrich RP, et al., A Laboratory Comparison of Pathogen Reduction
Technology Treatment and Culture of Platelet Products for Addressing Bacterial
Contamination Concerns. Transfusion 2009; 49: 1205-1216.
5. Cardo LJ, et al., Pathogen Inactivation of Leishmania Donovani Infantum in
Plasma and Platelet Concentrates Using Ribofavin and Ultraviolet Light.
Vox Sanguinis 2006; 90: 85-91.
6. Sullivan J, et al., Pathogen Inactivation of Plasmodium Falciparum in Plasma
and Platelet Concentrates With Ribofavin and UV Light. Vox Sanguinis 2008;
95 (Suppl. 1): 278-279.
7. Cardo LJ, et al., Pathogen Inactivation of Trypanosoma Cruzi in Plasma and
Platelet Concentrates Using Ribofavin and Ultraviolet Light. Transfusion and
Apheresis Science 2007; 37 (2): 131-137.
8. Tonnetti L, et al., Evaluation of the Mirasol Platelet Reduction Technology System
Against Babesia Microti in Apheresis Platelets and Plasma. Transfusion 2010,
in press.
9. Rentas F, et al., Inactivation of Orientia Tsutsugamushi in Red Blood Cells,
Plasma, and Platelets With Ribofavin and Light, as Demonstrated in an Animal
Model. Transfusion 2007; 47: 240-247.
10. Fast LD, et al., Functional Inactivation of White Blood Cells by Mirasol
Treatment. Transfusion 2006; 46: 642-648.
11. Fast LD, et al., Mirasol PRT Treatment of Donor White Blood Cells Prevents
the Development of Xenogeneic Graft-Versus-Host Disease in Rag
2-/-c-/-
Double
Knockout Mice. Transfusion 2006; 46: 1553-1560.
12. Asano H, et al., Treatment With Ribofavin and Ultraviolet Light Prevents
Alloimmunization to Platelet Transfusions and Cardiac Transplants.
Transplantation 2007; 84 (9): 1174-1182.
13. Hardwick CC, et al., Separation, Identifcation and Quantifcation of Ribofavin
and Its Photoproducts in Blood Products Using High-Performance Liquid
Chromotography With Fluorescence Detection: A Method to Support Pathogen
Reduction Technology. Photochemistry and Photobiology 2004; 80 (3): 609-615.
14. Reddy HL, et al., Toxicity Testing of a Novel Ribofavin-Based Technology for
Pathogen Reduction and White Blood Cell Inactivation. Transfusion Medicine
Reviews 2008; 22 (2): 133-153.
15. The Mirasol Clinical Evaluation Study Group, A Randomized Controlled Clinical
Trial Evaluating the Performance and Safety of Platelets Treated With Mirasol
Pathogen Reduction Technology. Transfusion 2010, in press.
16. Smith J and G Rock, Protein Quality in Mirasol Pathogen Reduction Technology-
Treated, Apheresis-Derived Fresh-Frozen Plasma. Transfusion 2010; 50: 926-931.
17. Hornsey VS, et al., Pathogen Reduction of Fresh Plasma Using Ribofavin and
Ultraviolet Light: Effects on Plasma Coagulation Proteins. Transfusion 2009 49:
2167-2172.
18. Larrea L, et al., The Infuence of Ribofavin Photochemistry on Plasma
Coagulation Factors. Transfusion and Apheresis Science 2009; 41: 199-204.
* Platelet additive solution (PAS) may need to be added after illumination to platelet concentrates with reduced plasma content to ensure adequate storage
conditions for up to 5 days
a White blood cells (WBCs): Inactivation
of WBCs in donated blood products may
reduce immunological complications of
transfusion
10-12
YOUR SYSTEM FOR
PLATELETS AND PLASMA
Mirasol PRT is the obvious choice
for pathogen reduction
The Mirasol system is designed to be effective against a broad range of
pathogens while still maintaining the quality of apheresis and whole
blood-derived blood products. Performance demonstrated against:
a Viruses: Enveloped and non-enveloped
1-3
a Bacteria: Gram negative and gram positive
4
a Parasites
5-9
Safety established
Mirasol-treated components have been shown to be safe for transfusion recipients as well as for those
who handle blood products.
Ribofavin is non-toxic and non-mutagenic; no additional precautionary measures necessary for staff
Ribofavin and its photoproducts are already present in human blood and do not need to be removed
from blood products prior to transfusion
13
The safety of the Mirasol process has been demonstrated through extensive toxicology testing
14
No adverse events were attributed to the use of Mirasol-treated platelet products or to the use of the
Mirasol PRT system in a well-controlled patient trial
15
Effcacy maintained
Reduce pathogen load while providing quality platelets and fresh frozen plasma (FFP).
The MIRACLE clinical trial confrmed no increased need for platelet or red blood cell transfusions
in patients receiving Mirasol-treated platelets
15
This trial also showed Corrected Count Increments (CCI) remained stable throughout multiple
transfusions of Mirasol-treated platelets
15

Mirasol-treated FFP preserves levels of coagulants and anticoagulants that meet the
Council of Europe guidelines for untreated FFP
16-18

Simplicity by design
Easy to learn. Easy to operate. Flexible. Limited handling and minimal product loss with the Mirasol
process help keep your operations effcient. In addition, our fully integrated data capture and storage
software system, the Mirasol Manager, ensures accurate reporting and simplifed data management.
Platelets are ready to
store* or transfuse
Plasma is ready to store
after transfer to fnal
freezing/storage bag
Transfer product to
illumination bag
Add
ribofavin
Illuminate for
4 to 10 minutes 1 2 3
References
1. Ruane PH, et al., Photochemical Inactivation of Selected Viruses and Bacteria in
Platelet Concentrates Using Ribofavin and Light. Transfusion 2004; 44: 877-885.
2. Goodrich RP, et al., The Mirasol PRT System for Pathogen Reduction of Platelets
and Plasma: An Overview of Current Status and Future Trends. Transfusion and
Apheresis Science 2006; 35 (1): 5-17.
3. Goodrich RP, et al., Chapter 5: The Antiviral and Antibacterial Properties of
Ribofavin and Light: Applications to Blood Safety and Transfusion Medicine.
Flavins: Photochemistry and Photobiology, Vol. 6, 2006, Royal Society of
Chemistry; Cambridge, United Kingdom. E Silva and AM Edwards, editors.
4. Goodrich RP, et al., A Laboratory Comparison of Pathogen Reduction
Technology Treatment and Culture of Platelet Products for Addressing Bacterial
Contamination Concerns. Transfusion 2009; 49: 1205-1216.
5. Cardo LJ, et al., Pathogen Inactivation of Leishmania Donovani Infantum in
Plasma and Platelet Concentrates Using Ribofavin and Ultraviolet Light.
Vox Sanguinis 2006; 90: 85-91.
6. Sullivan J, et al., Pathogen Inactivation of Plasmodium Falciparum in Plasma
and Platelet Concentrates With Ribofavin and UV Light. Vox Sanguinis 2008;
95 (Suppl. 1): 278-279.
7. Cardo LJ, et al., Pathogen Inactivation of Trypanosoma Cruzi in Plasma and
Platelet Concentrates Using Ribofavin and Ultraviolet Light. Transfusion and
Apheresis Science 2007; 37 (2): 131-137.
8. Tonnetti L, et al., Evaluation of the Mirasol Platelet Reduction Technology System
Against Babesia Microti in Apheresis Platelets and Plasma. Transfusion 2010,
in press.
9. Rentas F, et al., Inactivation of Orientia Tsutsugamushi in Red Blood Cells,
Plasma, and Platelets With Ribofavin and Light, as Demonstrated in an Animal
Model. Transfusion 2007; 47: 240-247.
10. Fast LD, et al., Functional Inactivation of White Blood Cells by Mirasol
Treatment. Transfusion 2006; 46: 642-648.
11. Fast LD, et al., Mirasol PRT Treatment of Donor White Blood Cells Prevents
the Development of Xenogeneic Graft-Versus-Host Disease in Rag
2-/-c-/-
Double
Knockout Mice. Transfusion 2006; 46: 1553-1560.
12. Asano H, et al., Treatment With Ribofavin and Ultraviolet Light Prevents
Alloimmunization to Platelet Transfusions and Cardiac Transplants.
Transplantation 2007; 84 (9): 1174-1182.
13. Hardwick CC, et al., Separation, Identifcation and Quantifcation of Ribofavin
and Its Photoproducts in Blood Products Using High-Performance Liquid
Chromotography With Fluorescence Detection: A Method to Support Pathogen
Reduction Technology. Photochemistry and Photobiology 2004; 80 (3): 609-615.
14. Reddy HL, et al., Toxicity Testing of a Novel Ribofavin-Based Technology for
Pathogen Reduction and White Blood Cell Inactivation. Transfusion Medicine
Reviews 2008; 22 (2): 133-153.
15. The Mirasol Clinical Evaluation Study Group, A Randomized Controlled Clinical
Trial Evaluating the Performance and Safety of Platelets Treated With Mirasol
Pathogen Reduction Technology. Transfusion 2010, in press.
16. Smith J and G Rock, Protein Quality in Mirasol Pathogen Reduction Technology-
Treated, Apheresis-Derived Fresh-Frozen Plasma. Transfusion 2010; 50: 926-931.
17. Hornsey VS, et al., Pathogen Reduction of Fresh Plasma Using Ribofavin and
Ultraviolet Light: Effects on Plasma Coagulation Proteins. Transfusion 2009 49:
2167-2172.
18. Larrea L, et al., The Infuence of Ribofavin Photochemistry on Plasma
Coagulation Factors. Transfusion and Apheresis Science 2009; 41: 199-204.
* Platelet additive solution (PAS) may need to be added after illumination to platelet concentrates with reduced plasma content to ensure adequate storage
conditions for up to 5 days
a White blood cells (WBCs): Inactivation
of WBCs in donated blood products may
reduce immunological complications of
transfusion
10-12
YOUR SYSTEM FOR
PLATELETS AND PLASMA
Mirasol PRT is the obvious choice
for pathogen reduction
P a t h o g e n r e d u c t i o n m a d e s i m p l e
S a f e g u a r d i n g t h e b l o o d s u p p l y i s c r i t i c a l . P a t h o g e n r e d u c t i o n p r o v i d e s y o u t h a t
a d d e d m e a s u r e o f s e c u r i t y a g a i n s t d i s e a s e - c a u s i n g a g e n t s , i n c l u d i n g v i r u s e s ,
p a r a s i t e s , b a c t e r i a a n d w h i t e b l o o d c e l l s .
N a t u r a l l y , y o u w a n t a p a r t n e r y o u c a n t r u s t .
T h e M i r a s o l P a t h o g e n R e d u c t i o n T e c h n o l o g y ( P R T ) s y s t e m u n i q u e l y u s e s t h e
p r o p e r t i e s o f r i b o f a v i n ( v i t a m i n B 2 ) a n d u l t r a v i o l e t l i g h t t o r e d u c e t h e i n f e c t i o u s
p a t h o g e n l o a d a n d i n a c t i v a t e r e s i d u a l w h i t e b l o o d c e l l s i n b l o o d p r o d u c t s * .
T h e M i r a s o l s y s t e m r e n d e r s p a t h o g e n s h a r m l e s s b y u s i n g a n o n - m u t a g e n i c ,
n o n - t o x i c m e t h o d , e l i m i n a t i n g t h e n e e d t o r e m o v e p h o t o c h e m i c a l a g e n t s p r i o r
t o t r a n s f u s i o n m a k i n g y o u r t r e a t e d b l o o d p r o d u c t s i m m e d i a t e l y a v a i l a b l e
t o t r e a t p a t i e n t s .
U s i n g a s i n g l e , i n t e g r a t e d s y s t e m f o r p l a t e l e t s a n d p l a s m a , C a r i d i a n B C T s
p r o p r i e t a r y p r o c e s s d e l i v e r s :
S a f e t y | E f f c a c y | S i m p l i c i t y
* T h e M i r a s o l s y s t e m h a s r e c e i v e d t h e C E m a r k f o r p l a t e l e t s a n d p l a s m a a n d i s u n d e r d e v e l o p m e n t f o r t h e t r e a t m e n t o f w h o l e b l o o d
H e l p i n g y o u k e e p t h e b l o o d s u p p l y
s a f e i s o u r h i g h e s t p r i o r i t y .
T h e M i r a s o l

s y s t e m s h i n e s n e w
l i g h t o n p a t h o g e n r e d u c t i o n .
Learn more
The Mirasol PRT system can help you provide safer blood products today.
Contact your CaridianBCT sales representative or visit www.caridianbct.com
for additional information.
2 0 1 0 C a r i d i a n B C T , I n c . P N 3 0 6 6 9 0 - 2 3 2
C a r i d i a n B C T , I n c .
1 0 8 1 1 W . C o l l i n s A v e n u e
L a k e w o o d , C o l o r a d o 8 0 2 1 5 - 4 4 4 0
U S A
U S A P h o n e : 1 . 8 7 7 . 3 3 9 . 4 2 2 8
P h o n e : + 1 . 3 0 3 . 2 3 1 . 4 3 5 7
F a x : + 1 . 3 0 3 . 5 4 2 . 5 2 1 5
C a r i d i a n B C T E u r o p e N . V .
E u r o p e , M i d d l e E a s t a n d A f r i c a
I k a r o s l a a n 4 1
1 9 3 0 Z a v e n t e m
B e l g i u m
P h o n e : + 3 2 . 2 . 7 1 5 . 0 5 . 9 0
F a x : + 3 2 . 2 . 7 2 1 . 0 7 . 7 0
C a r i d i a n B C T ( A s i a P a c i f c ) L t d .
R o o m 3 9 0 3 - 3 9 0 3 A , 3 9 / F
N e w Y o r k L i f e T o w e r , W i n d s o r H o u s e
3 1 1 G l o u c e s t e r R o a d
C a u s e w a y B a y , H o n g K o n g
P h o n e : + 8 5 2 . 2 2 8 3 . 0 7 0 0
F a x : + 8 5 2 . 2 5 7 6 . 1 3 1 1
C a r i d i a n B C T L a t i n A m e r i c a
J u n c a l 1 3 1 1 4 t h F l o o r
C 1 0 6 2 A B O
B u e n o s A i r e s
A r g e n t i n a
P h o n e : + 5 4 . 1 1 . 5 5 3 0 . 5 2 0 0
F a x : + 5 4 . 1 1 . 5 5 3 0 . 5 2 0 1
w w w . c a r i d i a n b c t . c o m
Pathogen reduction made simple
Safeguarding the blood supply is critical. Pathogen reduction provides you that
added measure of security against disease-causing agents, including viruses,
parasites, bacteria and white blood cells.
Naturally, you want a partner you can trust.
The Mirasol Pathogen Reduction Technology (PRT) system uniquely uses the
properties of ribofavin (vitamin B2) and ultraviolet light to reduce the infectious
pathogen load and inactivate residual white blood cells in blood products*.
The Mirasol system renders pathogens harmless by using a non-mutagenic,
non-toxic method, eliminating the need to remove photochemical agents prior
to transfusion making your treated blood products immediately available
to treat patients.
Using a single, integrated system for platelets and plasma, CaridianBCTs
proprietary process delivers:
Safety | Effcacy | Simplicity
*The Mirasol system has received the CE mark for platelets and plasma and is under development for the treatment of whole blood
Helping you keep the blood supply
safe is our highest priority.
The Mirasol

system shines new

light on pathogen reduction.
L e a r n m o r e
T h e M i r a s o l P R T s y s t e m c a n h e l p y o u p r o v i d e s a f e r b l o o d p r o d u c t s t o d a y .
C o n t a c t y o u r C a r i d i a n B C T s a l e s r e p r e s e n t a t i v e o r v i s i t w w w . c a r i d i a n b c t . c o m
f o r a d d i t i o n a l i n f o r m a t i o n .
2010 CaridianBCT, Inc. PN 306690-232
CaridianBCT, Inc.
10811 W. Collins Avenue
Lakewood, Colorado 80215-4440
USA
USA Phone: 1.877.339.4228
Phone: +1.303.231.4357
Fax: +1.303.542.5215
CaridianBCT Europe N.V.
Europe, Middle East and Africa
Ikaroslaan 41
1930 Zaventem
Belgium
Phone: +32.2.715.05.90
Fax: +32.2.721.07.70
CaridianBCT (Asia Pacifc) Ltd.
Room 3903-3903A, 39/F
New York Life Tower, Windsor House
311 Gloucester Road
Causeway Bay, Hong Kong
Phone: +852.2283.0700
Fax: +852.2576.1311
CaridianBCT Latin America
Juncal 1311 4th Floor
C1062ABO
Buenos Aires
Argentina
Phone: +54.11.5530.5200
Fax: +54.11.5530.5201
www.caridianbct.com